Committee MemberEmploymentConsultantSpeakers BureauOwnership/Partnership/PrincipalPersonal ResearchInstitutional, Organizational, or Other Financial BenefitExpert WitnessVoting Recusals By Section
Clyde W. Yancy (Chair)Northwestern University Feinberg School of Medicine, Division of Cardiology—Professor of Medicine and Chief; Diversity and Inclusion—Vice DeanNoneNoneNoneNoneNoneNoneNone
Mariell Jessup (Vice Chair)Fondation Leducq—Chief Scientific OfficerNoneNoneNoneNoneNoneNoneNone
Biykem BozkurtBaylor College of Medicine, Department of Medicine—Professor of Medicine; Cardiology Section, DeBakey VA Medical Center—Chief; The Mary and Gordon Cain Chair & W.A. “Tex” and Deborah Moncrief, Jr.—Chair; Winters Center for Heart Failure Research—Director; Cardiovascular Research Institute—Associate DirectorNoneNoneNone
  • Novartis

NoneNone7.3.2.10, 7.3.2.11, 7.3.3, and 9.5.
Javed ButlerStony Brook University—Division Chief of Cardiology
  • Bayer

  • Boehringer Ingelheim

  • CardioCell

  • Luitpold

  • Medtronic

  • Merck

  • Novartis

  • Relypsa

  • Takeda

  • Trevena

  • Z Pharma

  • Zensun

  • Novartis

None
  • Amgen (DSMB)

NoneNone7.3.2.10, 7.3.2.11, 7.3.3, and 9.5.
Donald E. Casey, JrThomas Jefferson College of Population Health— Faculty; Alvarez & Marsal IPO4Health—Principal and FounderNoneNoneNoneNoneNoneNoneNone
Monica M. ColvinUniversity of Michigan—Associate Professor of Medicine, CardiologyNoneNoneNoneNoneNoneNoneNone
Mark H. DraznerUniversity of Texas Southwestern Medical Center—Professor, Internal MedicineNoneNoneNoneNoneNoneNoneNone
Gerasimos S. FilippatosNational and Kapodistrian University of Athens; Attikon University Hospital, Department of Cardiology, Heart Failure Unit—Professor of CardiologyNoneNoneNone
  • Bayer

  • Bayer (DSMB)

  • Novartis

  • Servier Pharmaceuticals

  • Vifor

NoneNone7.3.2.10, 7.3.2.11, 7.3.3, 9.2, and 9.5.
Gregg C. FonarowAhmanson-UCLA Cardiomyopathy Center—Director; UCLA Division of Cardiology—Co-Chief
  • Amgen

  • Janssen Pharmaceuticals

  • Novartis

NoneNone
  • Novartis

NoneNone7.3.2.10, 7.3.2.11, 7.3.3, and 9.5.
Michael M. GivertzBrigham and Women's Hospital—Professor of Medicine
  • Merck

  • Novartis

NoneNoneNoneNoneNone7.3.2.10, 7.3.2.11, 7.3.3, and 9.5.
Steven M. HollenbergCooper University Hospital—Director, Coronary Care Unit, Professor of MedicineNoneNoneNoneNoneNoneNoneNone
JoAnn LindenfeldVanderbilt Heart and Vascular Institute—Director, Advanced Heart Failure and Transplant Section—Professor of Medicine
  • Abbott

  • Janssen Pharmaceuticals

  • Novartis

  • Relypsa

  • ResMed

NoneNone
  • AstraZeneca

  • Novartis

NoneNone6.3, 7.3.2.10, 7.3.2.11, 7.3.3, 9.5, and 9.6.
Frederick A. MasoudiUniversity of Colorado, Anschutz Medical Campus—Professor of Medicine, Division of CardiologyNoneNoneNoneNoneNoneNoneNone
Patrick E. McBrideUniversity of Wisconsin School of Medicine and Public Health—Professor of Medicine and Family Medicine; Associate Director, Preventive CardiologyNoneNoneNoneNoneNoneNoneNone
Pamela N. PetersonUniversity of Colorado, Denver Health Medical Center—Associate Professor of Medicine, Division of CardiologyNoneNoneNoneNoneNoneNoneNone
Lynne Warner StevensonBrigham and Women’s Hospital Cardiovascular Division—Director, Cardiomyopathy and Heart Failure ProgramNoneNoneNone
  • Novartis—PARENT trial (PI)

  • NHLBI—INTERMACS (Co–PI)

NoneNone7.3.2.10, 7.3.2.11, 7.3.3, and 9.5.
Cheryl WestlakeAzusa Pacific University, School of Nursing, Doctoral Programs—ProfessorNoneNoneNoneNoneNoneNoneNone

This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted.

According to the ACC/AHA, a person has a relevant relationship IF: a) The relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person’s household has a reasonable potential for financial, professional, or other personal gain or loss as a result of the issues/content addressed in the document.

ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; AHA, American Heart Association; DCRI, Duke Clinical Research Institute; DSMB, data safety monitoring board; HFSA, Heart Failure Society of America; NHLBI, National Heart, Lung, and Blood Institute; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; PARENT, Pulmonary artery pressure reduction with entresto; UCLA, University of California, Los Angeles; and VA, Veterans Affairs.

  • Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply.

  • Significant relationship.